

目 录

Content

乳腺癌 (Breast Cancer)

摘要
页码

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. [Abstract# 5]	1
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. [Abstract#500]	2
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. [Abstract#502]	3
Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). [Abstract#511]	4
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2. [Abstract#LBA509]	5
10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.[Abstract#1000]	6
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). [Abstract#1004]	7
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.[Abstract#1007]	8
S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. [Abstract#1008]	9
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). [Abstract#LBA1001]	11

癌症预防 (Cancer Prevention)

Visual inspection with acetic acid (VIA) screening by primary health workers reduces cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India. [Abstract#2]	12
--	----

中枢神经系统肿瘤 (Central Nervous System Tumors)

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). [Abstract#1]	13
A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. [Abstract#2001]	14
Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. [Abstract#2003]	15
Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors. [Abstract#2006]	16
Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial. [Abstract#LBA2000]	17

治疗进展——临床药理和试验性疗法

Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. [Abstract#2500]	18
Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. [Abstract#2503]	19
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC). [Abstract#2513]	20
A phase I study of the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies. [Abstract#2516]	21

Safety, pharmacokinetics, and preliminary activity of the α -specific PI3K inhibitor BYL719: Results from the first-in-human study. [Abstract#2531]	22
消化系肿瘤 (Gastrointestinal Cancer)	
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). [Abstract#3502]	23
A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. [Abstract#3504]	24
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. [Abstract#3505]	25
Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. [Abstract#3515]	26
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). [Abstract#LBA3506]	28
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. [Abstract#4005]	29
JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. [Abstract#4008]	30
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. [Abstract#4023]	31
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial. [Abstract#LBA4001]	32
SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. [Abstract#LBA4002]	34

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. [Abstract#LBA4003]	35
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. [Abstract#LBA4004]	36
泌尿系统肿瘤 (Genitourinary Cancer)	
Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). [Abstract#4504]	37
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. [Abstract#LBA4500]	38
Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial. [Abstract#LBA4510]	39
Prolaris: A novel genetic test for prostate cancer prognosis. [Abstract#5005]	40
Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). [Abstract#5009]	41
妇科肿瘤 (Gynecologic Cancer)	
Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. [Abstract#3]	43
Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC HORUS trial. [Abstract#5500]	44
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). [Abstract#5505]	46
A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)– European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)–Gynecologic Cancer Intergroup (GCIG) trial. [Abstract#LBA5501]	47

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16). [Abstract#LBA5503]	48
---	----

头颈部肿瘤 (Head and Neck Cancer)

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. [Abstract#4].....	49
The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. [Abstract#6009]	50

健康服务研究 (Health Services Research)

Randomized trial of a web-based intervention to address barriers to clinical trials. [Abstract#6500]	51
Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials. [Abstract#6501]	52
Off-label and compendia use of chemotherapy in patients with metastatic cancer. [Abstract#6509]	53
Impact of oncology drug shortages. [Abstract#6510]	54
Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia. [Abstract#7001]	55
A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. [Abstract#7002]	57
Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. [Abstract#7004]	58
A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K δ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) \geq 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [Abstract#7005]	60

肺癌 (Lung Cancer)

START: A phase III study of L-BLP25 (tecemotide) cancer immunotherapy for unresectable stage III non-small cell lung cancer. [Abstract#7500]	61
--	----

A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. [Abstract#7501]	62
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). [Abstract#7503]	63
Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE). [Abstract#7506]	65
Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). [Abstract#8021]	66
A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). [Abstract#CRA8007]	67
Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). [Abstract#8008]	68
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. [Abstract#8010]	69
Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). [Abstract#LBA8003]	70
Randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). [Abstract#LBA8005]	71
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial. [Abstract#LBA8011]	72

淋巴瘤和浆细胞病 (Lymphoma and Plasma Cell Disorders)

Tolerability and activity of combinations of the PI3K δ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. [Abstract#8500]	73
Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine. [Abstract#8503]	74
Utility of post-therapy surveillance scans in DLBCL. [Abstract#8504]	75
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. [Abstract#8509]	76
MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). [Abstract#8510]	78
黑色素瘤/皮肤癌 (Melanoma/Skin Cancers)	
Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). [Abstract#CRA9003]	79
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608. [Abstract#CRA9007]	80
Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (1 of 3) [Abstract#9009]	81
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2 of 3) [Abstract#9010]	82
Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. (3 of 3) [Abstract#9011]	83
Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). [Abstract#9012]	84
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. [Abstract#LBA9008]	85

患者和生存者护理 (Patient and Survivor Care)

A multicenter, randomized, double-blinded, placebo-controlled trial of modafinil for lung cancer-related fatigue: Dose response and patient satisfaction data. [Abstract#9503]	86
Biomarker prediction of chemotherapy-related amenorrhea. [Abstract#9508]	87
Predictive factors for chemotherapy feasibility in elderly patients with solid tumor: Results of GERCOR old prospective multicenter study. [Abstract#9511]	88
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC). [Abstract#LBA9514]	89